TY - JOUR
AU - Kennedy, Nicholas A.
AU - Lin, Simeng
AU - Goodhand, James R.
AU - Chanchlani, Neil
AU - Hamilton, Benjamin
AU - Bewshea, Claire
AU - Nice, Rachel
AU - Chee, Desmond
AU - Cummings, James
AU - Fraser, Aileen
AU - Irving, Peter M
AU - Kamperidis, Nikolaos
AU - Kok, Klaartje B.
AU - Lamb, Christopher A.
AU - MacDonald, Jonathan
AU - Mehta, Shameer
AU - Pollok, Richard
AU - Raine, Tim
AU - Smith, Philip J
AU - Verma, Ajay Mark
AU - Jochum, Simon
AU - McDonald, Timothy J.
AU - Sebastian, Shaji
AU - Lees, Charlie W
AU - Powell, Nick
AU - Ahmad, Tariq
PY - 2021
DA - April
TI - Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
JO - Gut
EP - 1893
VL - 70
IS - 10
DO - http://dx.doi.org/10.1136/gutjnl-2021-324789
AB - OBJECTIVE: Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine.
PB - BMJ Publishing Group
UR - https://www.research.ed.ac.uk/en/publications/234b6c65-3188-49a4-aebb-ee9d63b0a877
KW - Coronavirus (COVID-19)
KW - Hospital care
KW - Immunisation and screening
ER